Navigation Links
DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Date:10/20/2011

cile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to the DIFICID's potential as a treatment for CDAD compared to other therapies and the incidence and costs of CDAD. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: whether healthcare professionals will prescribe DIFICID, the extent to which DIFICID will be accepted on hospital formularies, the development of alternative means of preventing or treating DIFICID, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.  Forward-looking statements speak only as of the date of this release, and Optimer undertakes no obligation to update or revise these statements, except as may be required by law.

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
2. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
3. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
9. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
10. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
11. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... April 30, 2015 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the fourth ... Fourth quarter and fiscal 2015 overview: , ... fourth quarter, up 33% over last year,s comparable quarter, ... , Diluted EPS of $0.50 for the fourth ...
(Date:4/30/2015)... 2015  Accuray Incorporated (Nasdaq: ARAY ) ... with MIM Software Inc. to further develop adaptive ... ® product portfolios. The new software solution ... is Accuray,s second collaboration with MIM; the previous ... iPad-based treatment plan review capability, PlanTouch™. ...
(Date:4/30/2015)...  Tandem Diabetes Care ® , Inc. (NASDAQ: TNDM ... ® and t:flex™ Insulin Pumps, today reported its financial ... In comparing the first quarter of 2015 to the ... to $12.3 million from $8.1 million , t:slim Pump ... "Our investment in resources to build the foundation ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6
... Fortis Healthcare, India,s leading provider of ... and Masimo (NASDAQ: MASI ) ... allows Fortis hospitals access to Masimo,s full line of ... continuous patient monitoring solutions. As part ...
...  PAREXEL International Corporation (NASDAQ: PRXL ) will release ... on Monday, April 30, 2012 after the close of the ... at www.PAREXEL.com and on the PR Newswire website ... conference call and live webcast at 10:00 a.m. ET on ...
Cached Medicine Technology:Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 2Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 3Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 4Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 5Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 6Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 7Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 8PAREXEL Announces Date of Third Quarter Fiscal Year 2012 Earnings Release and Conference Call 2
(Date:5/1/2015)... It’s raining bills on Capitol Hill with members in ... support for telemedicine. , “Such action is unprecedented ... Congress,” said Jonathan Linkous, CEO of the American Telemedicine Association ... to embrace the use of telecommunications in the delivery of ... mission to improve quality, access, equity and affordability of healthcare.”, ...
(Date:5/1/2015)... Ernst & Young (EY) has announced ... & CSO, and Burak Sezen, Co-Founder & CTO of ... Entrepreneur Of The Year® 2015 Awards in the Ohio ... a global leader in assurance, tax, transaction and advisory ... the top audit companies in the world. The awards ...
(Date:5/1/2015)... 2015 The Quail Creek Relay for Life ... Since 2001, the Quail Creek Relay team has raised almost ... throughout the year, including their biggest event, January’s Dinner and ... , Quail Creek Relay for Life team was established ... Kerwin, fitness director, states, “I was hooked when I learned ...
(Date:5/1/2015)... May 01, 2015 As the sale ... its 18-month anniversary, many people in the industry are ... , According the latest annual report by the ... percent in 2014, and reached nearly $3 billion in ... love affair with cannabis, combined with the ongoing economic ...
(Date:5/1/2015)... RICHMOND, VA (PRWEB) May 01, 2015 ... announce partnerships with the Hickory Crawdads (NC) and the ... sweetFrog will have in-stadium concession locations and offer fans ... a part of the Hickory Community,” said Luke Shook, ... is a great opportunity and we look forward to ...
Breaking Medicine News(10 mins):Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 3Health News:sweetFrog Announces Minor League Baseball Partnerships 2
... help surgeons limit nerve damage while performing a robotic ... according to a study performed at the University of ... used to evaluate 38 neurovascular bundles in 19 men ... the neurovascular resection plan in 20/38 neurovascular bundles," said ...
... which is a highly effective colorectal screening test, is feasible ... to a study performed at the University of Arizona in ... performed on 86 patients at two remote medical centers (343 ... performed CTC on the patients and the data obtained was ...
... saves a life. Saturday, April 25 is World Malaria Day. , ... ... teaming up with the United Nations Foundation and its Nothing But Nets ... his New Look Foundation, Raymond and the UN Foundation will provide opportunities ...
... 2009 -- In "Only 10 Seconds to Care: Help and ... the book publishing program of the American College of Physicians ... about the healing power of compassionate words and actions that ... a world of difference to patients. , "Because of demands ...
... Beyond Basic NutritionNEW ORLEANS, April 23 Data ... New Orleans suggest raisin and dried fruit consumption ... obesity. The analysis examined the association between dried ... in adults 19 years old and older, using ...
... today an exclusive distribution agreement with ELITech UK Limited ... Kingdom. The distribution agreement marks the beginning of ... expands its reach both in scope and geography. ... in surgery suites and catheterization labs within UK hospitals ...
Cached Medicine News:Health News:'Only 10 Seconds to Care' by Dr. Wendy S. Harpham helps heal clinician-patient bonds 2Health News:Raisin and Dried Fruit Consumption Associated With Reduced Abdominal Obesity 2Health News:Accumetrics, Inc. Announces United Kingdom Distribution Agreement With ELITech UK Limited 2
The moist air humidifying chamber is designed for the infusion of humidified air during phakic fluid air exchange. Sterile single-use. 10 per box. Most popular size or model....
Used with eye shield to cushion the eye. Eliminates need for taping shield. No sticky residue. Package 50 per box. Assorted colors....
Child size. Clear plastic. Accommodates either eye. Packaged 12 per box. Available in either adult or pediatric size....
... 45 cc/minute. Pore size: ... fluids at flow rate ... membrane support rated at ... via prefilled syringe and ...
Medicine Products: